Skip to content
2000
Volume 8, Issue 15
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Quinone based bioreductive drugs have, potentially, a very versatile use in cancer chemotherapy. They can be activated by DT-diaphorase and hence can be used to target tumour types rich in this O2- independent reductase enzyme. Small molecular modifications can substantially reduce specificity for DTdiaphorase and under these circumstances the quinones become much less toxic in air but retain their potent cytotoxic effects under hypoxic conditions. Our understanding of the reductive (bio) chemistry of indolequinones, in particular, has subsequently allowed us to develop a platform technology where almost any therapeutic entity can potentially be delivered, selectively, to hypoxic tumours. Antiangiogenic approaches are currently receiving a substantial amount of attention and this review brings their development into context in view of the hypoxia dependence for neovascularization. Lastly, the use of bioreductive drugs when combined with hypoxia-mediated gene therapy is described. Such an approach provides a unique dual level of specificity for targeting hypoxic tumours and potentially can provide substantial therapeutic benefit.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612023394548
2002-07-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612023394548
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test